IP Library › Granted Patent US 11,304,832
Granted Patent B2
US 11,304,832 · App. 16/392,283 · Granted Apr 19, 2022

Fenestrated stent system and method of use

Inventors: Mohamed Zayed (St. Louis, MO); Alexander J. Wirtz (St. Louis, MO)
Assignee: Washington University
A61F2/86A61F2/07A61F2002/065A61F2002/821A61F2230/0069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,304,832
App. No.
16/392,283
Granted
Apr 19, 2022
Kind
B2
Abstract

The disclosure provides for a device and method for treating aortoiliac occlusion disease with the placement of a fenestrated stent system at the aortic bifurcation. The fenestrated stent system includes a tapered fenestrated stent with a fenestration and a common iliac stent that is placed within the fenestration of the fenestrated stent.

Claims (28)

1. A fenestrated stent system for placement in the aortic bifurcation, the fenestrated stent system comprising:

a fenestrated stent having a distal aorta end and a common iliac end, the fenestrated stent comprising a fenestration at a point between the distal aorta end and the common iliac end and at least one radiopaque marker on an outer surface of the fenestrated stent; and

a common iliac stent having a proximal end and a distal end, the common iliac stent operable for placement through the fenestration of the fenestrated stent and in the contralateral common iliac artery,

wherein the fenestrated stent is tapered 45% to 80% from the distal aorta end to the common iliac end and the common iliac stent is tapered 5% to 25% from the proximal end to the distal end, and

wherein the fenestration comprises a radiopaque wireframe on the fenestration border.

2. The fenestrated stent system of claim 1 , wherein the fenestrated stent is 8 cm in length.

3. The fenestrated stent system of claim 1 , wherein the taper from the distal aorta end to the common iliac end is 50%.

4. The fenestrated stent system of claim 3 , wherein the distal aorta end has a diameter of 14 mm and the common iliac end has a diameter of 7 mm.

5. The fenestrated stent system of claim 1 , wherein the fenestration has an oval, circular, or triangular shape.

6. The fenestrated stent system of claim 5 , wherein the fenestration is oval-shaped and has a size of 10 mm by 8 mm.

7. The fenestrated stent system of claim 1 , wherein the fenestrated stent and the common iliac stent are balloon expandable.

8. The fenestrated stent system of claim 1 , wherein the at least one radiopaque marker is a series of radiopaque lines oriented perpendicular to one another on the outer surface of the fenestrated stent.

9. The fenestrated stent system of claim 1 , wherein the common iliac stent comprises at least one radiopaque marker.

10. A method of treating aortoiliac occlusion disease, comprising:

placing a fenestrated stent at a location in the aortic bifurcation, the fenestrated stent having a distal aorta end and a common iliac end an comprising a fenestration at a point between the distal aorta end and the common iliac end and at least one radiopaque marker on an outer surface of the fenestrated stent, wherein the fenestrated stent is tapered 45% to 80% from the distal aorta end to the common iliac end, and wherein the fenestration comprises a radiopaque wireframe on the fenestration border;

identifying the location of the fenestrated stent;

adjusting the fenestrated stent such that the distal aorta end is in the aorta and the common iliac end is in a common iliac;

identifying the location of the fenestration;

adjusting the fenestrated stent so that the fenestration aligns with the contralateral common iliac;

expanding a balloon to expand the fenestrated stent; and

placing a common iliac stent through the fenestration of the fenestrated stent and in the contralateral common iliac artery, wherein the common iliac stent is tapered 5% to 25% from a proximal end to a distal end of the common iliac stent.

11. The method of claim 10 , wherein the fenestrated stent is 8 cm in length.

12. The method of claim 10 , wherein the taper from the distal aorta end to the common iliac end is 50%.

13. The method of claim 12 , wherein the distal aorta end has a diameter of 14 mm and the common iliac end has a diameter of 7 mm.

14. The method of claim 10 , wherein the fenestration has an oval, circular, or triangular shape.

15. The method of claim 14 , wherein the fenestration is oval-shaped and has a size of 10 mm by 8 mm.

16. The method of claim 10 , wherein the at least one radiopaque marker is a series of radiopaque lines oriented perpendicular to one another on the outer surface of the fenestrated stent.

17. The method of claim 10 , wherein the common iliac stent comprises at least one radiopaque marker.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2019
From: ZAYED, MOHAMED; WIRTZ, ALEXANDER J.
To: WASHINGTON UNIVERSITY
Reel/Frame 050406/0914 →
Continuity (2)
Provisional Application 62661398 · Apr 23, 2018
Related Publication 20190321203A1 · Oct 24, 2019